When was Vivtex founded?

Vivtex was founded in 2018 and raised its 1st funding round 4 years after it was founded.

Where is Vivtex located?

Vivtex is headquartered in Cambridge, United States.

Who is the current CEO of Vivtex?

Douglas Eby of Vivtex. They have also founded 1 company.

How many employees does Vivtex have?

As of Apr 30, 2026, the latest employee count at Vivtex is 20.

Is Vivtex a funded company?

Vivtex is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Aug 19, 2022.

When was the latest funding round of Vivtex?

Vivtex's latest funding was a $***** Seed round on Aug 19, 2022, with participation from 0 investor.

Where does Vivtex rank among its competitors?

Vivtex ranks 9th amongst 60 active competitors, of which 14 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Cingulate, which secured $25M in Jul, 2025.

Who are the top competitors of Vivtex?

Vivtex's top competitors include Cingulate, Orbis Medicines and Lipocine. Among them, Cingulate secured the most recent funding round in July, 2025.

Vivtex - 2026 Company Profile, Team, Funding & Competitors

Vivtex is a seed company based in Cambridge (United States), founded in 2018 by C Giovanni Traverso, Douglas Eby, Thomas Von Erlach and Robert Langer. It operates as a Developer of oral drug delivery system. Vivtex has raised $1.8M in funding. The company has 60 active competitors, including 14 funded and 12 that have exited. Its top competitors include companies like Cingulate, Orbis Medicines and Lipocine.

Company Details

Developer of oral drug delivery system. The company is also developing programs that focus on the local delivery of antisense oligonucleotide and plasmid DNA therapeutics into GI tissue for the treatment of GI-related diseases. The Gastrointestinal Organ Robotic Interface System (GI-ORIS) and proprietary algorithms enable real-time automated data reporting and are integrated into the electronic inventory and experimental reporting system.

Website: vivtex.com
Email ID: *****@vivtex.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

Cambridge, United States

Stage

Seed

Total Funding

$1.8M in 1 round

Latest Funding Round

Seed, Aug 19, 2022, $*****

Ranked

9^th among 60 active competitors

Employee Count

20 as on Apr 30, 2026

Similar Companies

Genedit & 79 more

View Vivtex's full profile

Vivtex is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VIVITEX CORPORATION CIN: 830902645 , United States, Active	Apr 26, 2020	-	10 (As on Dec 31, 2022)	-

Vivtex has raised a total funding of $1.8M over 1 round.

Here is the list of recent funding rounds of Vivtex:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 19, 2022	6473854	Seed	4236721	8123355	6788579	8406157

Access funding benchmarks and valuations. Sign up today!

View details of Vivtex's funding rounds and investors

The founders of Vivtex are C Giovanni Traverso, Douglas Eby, Thomas Von Erlach and Robert Langer. Douglas Eby is the CEO of Vivtex.

Here are the details of Vivtex's key team members:

C Giovanni Traverso: Co-Founder of Vivtex and founder of 6 other companies, including Teal Bio, Suono Bio and Celero Systems.
Douglas Eby: Co-Founder & CEO of Vivtex.
Contact Info: 1 email address
Thomas Von Erlach: Co-Founder & CSO of Vivtex.
Robert Langer: Co-Founder of Vivtex.

View details of Vivtex's Founder profiles and Board Members

Vivtex's employee count trend

Vivtex has 20 employees as of Apr 26. Here is Vivtex's employee count trend over the years:

Uncover Vivtex's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vivtex include Cingulate, Orbis Medicines and Lipocine. Here is the list of Top 10 competitors of Vivtex, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cingulate 2012, Kansas City (United States), Public	Developer of therapeutics for the treatment of ADHD	$33M	The Werth Family Foundation, Lincoln Park Capital ... & 2 others	58/100
2nd	Orbis Medicines 2022, Copenhagen (Denmark), Series A	Provider of drug discovery platform to develop multiple therapeutics	$126M	New Enterprise Associates, Novo Holdings & 4 others	55/100
3rd	Lipocine 1997, Salt Lake City (United States), Public	Develops oral versions of hormones using Hydroance drug delivery technology	$38M	Foresite Capital	54/100
4th	PLx Pharma 2002, Sparta (United States), Public	Developer of drug delivery platform to treat gastrointestinal diseases	$25.3M	Aurus, HHS	53/100
5th	Cure Pharmaceutical 2010, Oxnard (United States), Public	Developer of oral thin film based drug delivery systems	$9.65M	Onbelay Capital, Hangar202 & 1 others	52/100
6th	Biograil 2019, Hedehusene (Denmark), Series B	Provider of technology for oral delivery of biologics	$28.4M	Evonik, Verve Ventures & 8 others	49/100
7th	G2GBIO 2017, Yuseong District (South Korea), Public	Developer of sustained release injectables	-	Korea Investment Holdings, BNK Venture Capital ... & 1 others	47/100
8th	OnDosis 2017, Gothenburg (Sweden), Series B	Developer of an oral drug delivery system	$14.5M	Aeternum, Astrazeneca & 7 others	47/100
9th	Vivtex 2018, Cambridge (United States), Seed	Developer of oral drug delivery system	$1.8M	-	53/100
10th	Lyndra 2015, Cambridge (United States), Deadpooled	Developer of oral drug delivery formulations	$305M	Polaris Partners, AIG & 24 others	45/100